Latest News

Recent paper on use of our Advax-CpG adjuvant in Herpes Simplex virus Vaccine development

This latest paper highlights a Herpes simplex virus vaccine being developed in collaboration with our Swedish partners. The Advax-CpG adjuvant in this herpes simplex vaccine is the same approach as we are using in our current COVID-19 vaccine. Link to the paper:

Vaxine announces partnership with Arrotex Pharmaceuticals

Australia’s biggest Australian-owned pharmaceutical company has put their support behind Vaxine’s Covid-19 vaccine. Arrotex Pharmaceuticals is poised to sign a manufacturing memorandum of understanding with Vaxine. Arrotex deal with Vaxine

CinnaGen Initiates a Phase 3 Clinical Trial of Vaxine’s COVID-19 Vaccine Technology

  On August 07, 2021, the first volunteer enrolled in the Phase 3 clinical study of Cinnagen’s COVID-19 vaccine candidate in Iran. The study is a randomized, double-blind, placebo-controlled trial and will evaluate the efficacy and safety of the vaccine in 16,876 adult participants. Subjects receive two doses, 21 days apart, of either Spikogen vaccine or […]